Leerink Partnrs Lifts Earnings Estimates for Tourmaline Bio

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share (EPS) forecast for Tourmaline Bio from ($1.00) to ($0.96), reflecting improved expectations for the company.
• Tourmaline Bio's reported EPS for the last quarter was ($0.90), which exceeded analysts' estimates of ($0.94).
• The company has received multiple "buy" ratings from analysts, with targets ranging from $50.00 to $70.00, indicating strong confidence in the stock's performance.

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Tourmaline Bio in a research note issued on Wednesday, August 13th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.96) per share for the quarter, up from their previous estimate of ($1.00). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's FY2025 earnings at ($3.61) EPS, FY2026 earnings at ($4.33) EPS, FY2027 earnings at ($5.52) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($4.51) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.04.

A number of other research firms also recently weighed in on TRML. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Guggenheim reissued a "buy" rating and set a $55.00 price objective on shares of Tourmaline Bio in a report on Thursday, August 14th. Finally, Chardan Capital reissued a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a report on Thursday, August 14th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $50.14.

Tourmaline Bio Trading Up 1.0%

TRML stock traded up $0.2240 during trading on Monday, reaching $22.6840. 37,981 shares of the stock were exchanged, compared to its average volume of 287,237. The firm's 50 day moving average is $19.25 and its 200 day moving average is $16.69. Tourmaline Bio has a twelve month low of $11.56 and a twelve month high of $29.79. The firm has a market cap of $582.64 million, a P/E ratio of -6.60 and a beta of 2.04.

Hedge Funds Weigh In On Tourmaline Bio

Institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after acquiring an additional 1,232 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Tourmaline Bio by 34.1% in the second quarter. BNP Paribas Financial Markets now owns 2,103 shares of the company's stock valued at $34,000 after purchasing an additional 535 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Tourmaline Bio by 35.7% in the second quarter. Tower Research Capital LLC TRC now owns 3,214 shares of the company's stock valued at $51,000 after purchasing an additional 846 shares in the last quarter. Brooklyn Investment Group grew its position in shares of Tourmaline Bio by 148.9% in the first quarter. Brooklyn Investment Group now owns 3,923 shares of the company's stock valued at $60,000 after purchasing an additional 2,347 shares in the last quarter. Finally, Virtus ETF Advisers LLC purchased a new position in shares of Tourmaline Bio in the fourth quarter valued at $64,000. Hedge funds and other institutional investors own 91.89% of the company's stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.